Linked Life Data

14599631

Source:http://linkedlifedata.com/resource/pubmed/id/14599631

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
7
pubmed:dateCreated
2003-11-5
pubmed:abstractText
To examine the effect of inappropriate initial antimicrobial therapy on the prognosis of patients with sepsis who were enrolled in a clinical trial of an immunomodulating agent conducted in 108 hospitals in North America and Europe.
pubmed:commentsCorrections
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Nov
pubmed:issn
0002-9343
pubmed:author
pubmed:issnType
Print
pubmed:volume
115
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
529-35
pubmed:dateRevised
2006-11-15
pubmed:meshHeading
pubmed-meshheading:14599631-Aged, pubmed-meshheading:14599631-Critical Illness, pubmed-meshheading:14599631-Cross Infection, pubmed-meshheading:14599631-Drug Resistance, Multiple, pubmed-meshheading:14599631-Female, pubmed-meshheading:14599631-Humans, pubmed-meshheading:14599631-Immunoglobulin G, pubmed-meshheading:14599631-Immunoglobulin Heavy Chains, pubmed-meshheading:14599631-Immunoglobulin gamma-Chains, pubmed-meshheading:14599631-Logistic Models, pubmed-meshheading:14599631-Male, pubmed-meshheading:14599631-Middle Aged, pubmed-meshheading:14599631-Odds Ratio, pubmed-meshheading:14599631-Receptors, Tumor Necrosis Factor, pubmed-meshheading:14599631-Recombinant Fusion Proteins, pubmed-meshheading:14599631-Sepsis, pubmed-meshheading:14599631-Shock, Septic, pubmed-meshheading:14599631-Tumor Necrosis Factor-alpha
pubmed:year
2003
pubmed:articleTitle
Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis.
pubmed:affiliation
Divisions of Infectious Diseases, University of Geneva Hospitals, Geneva, Switzerland. harbarth@post.harvard.edu
pubmed:publicationType
Journal Article, Clinical Trial, Research Support, Non-U.S. Gov't, Multicenter Study, Clinical Trial, Phase III